Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antiviral Oral Spray
- Development stage
- Phase 1
- Lead developer
- 三元基因
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Antiviral Oral Spray is a recombinant protein therapeutic developed by Triprime Gene (Beijing Tri-Prime Gene Pharmaceutical). It is formulated as a high-stability aqueous solution of recombinant human interferon alpha-1b (IFN-α1b) designed for localized delivery to the oropharyngeal mucosa via an oral spray. The drug functions by activating the interferon signaling pathway; specifically, it binds to the type I interferon receptors (IFNAR1 and IFNAR2) on the surface of target cells. This binding triggers the JAK-STAT signaling cascade, leading to the induction of various interferon-stimulated genes (ISGs) that establish an antiviral state in the local tissue. This mechanism inhibits viral entry, replication, and assembly, providing a protective barrier and therapeutic effect against viral oral infections. The product is approved in China for the treatment of viral infections of the mouth and throat.
- Brand names
- YundesuAntiviral Oral Spray
- Other names
- 抗病毒口腔喷雾剂Recombinant Human Interferon alpha-1b Oral SprayTriprime Antiviral Oral Spray
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on Antiviral Oral Spray.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antiviral Oral Spray.